MCID: IMM136
MIFTS: 52

Immune System Disease

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Immune System Disease

MalaCards integrated aliases for Immune System Disease:

Name: Immune System Disease 12 15 17
Abnormality of the Immune System 29
Immune System and Disorders 43
Immune System Diseases 72

Classifications:



External Ids:

Disease Ontology 12 DOID:2914
ICD9CM 35 279 279.9
ICD10 33 D89.9
UMLS 72 C0021053 C0041806

Summaries for Immune System Disease

MedlinePlus : 43 Your immune system is a complex network of cells, tissues, and organs that work together to defend against germs. It helps your body to recognize these "foreign" invaders. Then its job is to keep them out, or if it can't, to find and destroy them. If your immune system cannot do its job, the results can be serious. Disorders of the immune system include Allergy and asthma - immune responses to substances that are usually not harmful Immune deficiency diseases - disorders in which the immune system is missing one or more of its parts Autoimmune diseases - diseases causing your immune system to attack your own body's cells and tissues by mistake

MalaCards based summary : Immune System Disease, also known as abnormality of the immune system, is related to immune deficiency disease and temporal arteritis, and has symptoms including pathological conditions, signs and symptoms An important gene associated with Immune System Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Midazolam and Morphine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and brain, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A disease of anatomical entity that is located in the immune system.

Wikipedia : 75 The immune system is a host defense system comprising many biological structures and processes within an... more...

Related Diseases for Immune System Disease

Diseases related to Immune System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 immune deficiency disease 34.1 IL4 IL2 IL10 CD40LG
2 temporal arteritis 32.9 TNF SERPINA3 IL6 APOH
3 autoimmune disease 32.5 TNF MOG MBP IL6 IL4 IL2
4 bacterial infectious disease 31.1 TNF IL6 IL17A IL10
5 periodontitis 30.9 TNF IL6 IL4 IL17A IL10
6 peritonitis 30.8 TNF IL6 IL10
7 complement component 3 deficiency, autosomal recessive 11.5
8 leishmaniasis 11.1 TNF IL4 IL10
9 tropical endomyocardial fibrosis 11.0 TNF IL4 IL10
10 endomyocardial fibrosis 11.0 TNF IL4 IL10
11 optic neuritis 11.0 TNF MOG MBP
12 trichohepatoenteric syndrome 1 11.0
13 keratoconjunctivitis 11.0 TNF IL4 IL2
14 tungiasis 11.0 TNF IL4 IL10
15 chronic graft versus host disease 11.0 TNF IL10 CD4
16 polyclonal hypergammaglobulinemia 11.0 IL6 CD8A CD4
17 punctate inner choroidopathy 11.0 TNF IL10
18 xanthogranulomatous cholecystitis 11.0 SERPINA3 CD8A CD4
19 autoimmune atherosclerosis 11.0 IL10 FOXP3 APOH
20 pustulosis palmaris et plantaris 11.0 TNF CD40LG CCR6
21 apple allergy 11.0 IL4 IL10 FOXP3
22 conjunctivitis 11.0 IL6 IL4 IL2
23 pneumocystosis 11.0 TNF CD40LG CD4
24 vasculitis 11.0 TNF CD40LG APOH
25 orofacial granulomatosis 11.0 TNF IL4 IL10
26 buruli ulcer 11.0 IL4 IL10 CD40LG
27 balo concentric sclerosis 11.0 MOG MBP IFNB1
28 oral tuberculosis 11.0 TNF IL2
29 poliomyelitis 11.0 TNF IL4 IL10
30 gaucher disease, type ii 11.0 IL4 IL2 IL10
31 clonorchiasis 11.0 TNF IL2 IL10
32 melkersson-rosenthal syndrome 11.0 TNF CD8A CD4
33 ventilation pneumonitis 11.0 TNF CD4
34 streptococcal toxic-shock syndrome 11.0 TNF IL6 IL2
35 lichen disease 11.0 TNF IL4 FOXP3
36 central nervous system vasculitis 11.0 TNF IL6 IL17A
37 pneumonia 11.0 TNF IL6 IL10 CD40LG
38 immunodeficiency with hyper-igm, type 2 11.0 MOG ICOSLG CD40LG
39 internuclear ophthalmoplegia 11.0 MOG MBP IFNB1
40 autoinflammation, panniculitis, and dermatosis syndrome 11.0
41 allergic hypersensitivity disease 11.0
42 lymphatic system disease 11.0
43 herpes zoster 11.0
44 vasculitis syndromes of the central and peripheral nervous systems 11.0
45 cystic echinococcosis 11.0 IL6 IL17A IL10
46 primary systemic mycosis 11.0 TNF IL4 IL17A IL10
47 transient hypogammaglobulinemia of infancy 11.0 IL4 IL10 CD40LG
48 neuritis 11.0 TNF MOG MBP IL4
49 post-transplant lymphoproliferative disease 11.0 TNF IL6 IL10
50 autoimmune disease of peripheral nervous system 11.0 TNF MOG MBP

Graphical network of the top 20 diseases related to Immune System Disease:



Diseases related to Immune System Disease

Symptoms & Phenotypes for Immune System Disease

UMLS symptoms related to Immune System Disease:


pathological conditions, signs and symptoms

MGI Mouse Phenotypes related to Immune System Disease:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 CCR6 CD4 CD40LG CD8A CTLA4 FOXP3
2 immune system MP:0005387 10.38 CCR6 CD4 CD40LG CD8A CTLA4 FOXP3
3 homeostasis/metabolism MP:0005376 10.37 APOH CCR6 CD4 CD40LG CTLA4 FOXP3
4 cellular MP:0005384 10.33 CD4 CD40LG CD8A FOXP3 IL10 IL2
5 endocrine/exocrine gland MP:0005379 10.3 CD4 CD40LG CD8A CTLA4 FOXP3 IL10
6 mortality/aging MP:0010768 10.25 APOH CD4 CD40LG CD8A CTLA4 FOXP3
7 digestive/alimentary MP:0005381 10.19 CD4 CTLA4 FOXP3 IL10 IL17A IL2
8 nervous system MP:0003631 10.15 CCR6 CD4 CD40LG CD8A IFNB1 IL10
9 integument MP:0010771 10.11 CD4 CD40LG CD8A CTLA4 FOXP3 IL10
10 liver/biliary system MP:0005370 9.98 CTLA4 FOXP3 IL10 IL2 IL4 IL6
11 no phenotypic analysis MP:0003012 9.97 CD4 FOXP3 IFNB1 IL10 IL17A IL2
12 normal MP:0002873 9.91 CCR6 CD4 CD8A CTLA4 FOXP3 IFNB1
13 renal/urinary system MP:0005367 9.7 CD40LG CD8A FOXP3 IL17A IL4 IL6
14 respiratory system MP:0005388 9.56 CTLA4 FOXP3 IL10 IL17A IL2 IL4
15 vision/eye MP:0005391 9.23 FOXP3 IL10 IL2 IL4 IL6 MBP

Drugs & Therapeutics for Immune System Disease

Drugs for Immune System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
5
Fludarabine Approved Phase 4 21679-14-1, 75607-67-9 30751
6
Busulfan Approved, Investigational Phase 4 55-98-1 2478
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
9
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
10
Adenosine Approved, Investigational Phase 4 58-61-7 60961
11
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
12
Treosulfan Investigational Phase 4 299-75-2 9296
13 Central Nervous System Depressants Phase 4
14 Anesthetics, Intravenous Phase 4
15 Tranquilizing Agents Phase 4
16 Narcotics Phase 4
17 Anti-Anxiety Agents Phase 4
18 Adjuvants, Anesthesia Phase 4
19 Analgesics, Opioid Phase 4
20 Hypnotics and Sedatives Phase 4
21 GABA Modulators Phase 4
22 Anesthetics, General Phase 4
23 Psychotropic Drugs Phase 4
24 Antitubercular Agents Phase 4
25 Analgesics Phase 4
26 Analgesics, Non-Narcotic Phase 4
27 Cyclooxygenase Inhibitors Phase 4
28 Fibrinolytic Agents Phase 4
29 Peripheral Nervous System Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Platelet Aggregation Inhibitors Phase 4
32 Antipyretics Phase 4
33 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
34 Mesalamine Phase 4 89-57-6
35 Alkylating Agents Phase 4
36 Anti-Infective Agents Phase 4
37 Immunologic Factors Phase 4
38 Immunosuppressive Agents Phase 4
39 Antineoplastic Agents, Alkylating Phase 4
40 interferons Phase 4
41 Immunoglobulin A Phase 4
42 Antimalarials Phase 4
43 Antiparasitic Agents Phase 4
44 Antiprotozoal Agents Phase 4
45 Anticoagulants Phase 4
46 Interferon-alpha Phase 4
47 Antihypertensive Agents Phase 4
48 Angiotensinogen Phase 4
49 Angiotensin II Type 1 Receptor Blockers Phase 4
50 Angiotensin Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 207)
# Name Status NCT ID Phase Drugs
1 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
2 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
3 Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status. Unknown status NCT02135055 Phase 4 Midazolam;Morphine
4 The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Completed NCT01867281 Phase 4 aspirin
5 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
6 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
7 Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial Completed NCT02053740 Phase 4 Add R-S-Y-R-T (500 mg 3 times per day) for 6 months;Routine western medicine
8 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
9 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
10 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
11 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
12 Methodology Study to Investigate the Utility of Retroviral Insertion Site Analysis in Samples From Subjects Treated With Strimvelis™ Gene Therapy Not yet recruiting NCT03311074 Phase 4
13 A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis Unknown status NCT02468791 Phase 3 Rituximab
14 A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis Completed NCT01918033 Phase 3 Desloratadine 5 mg;Placebo
15 A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus. Completed NCT01916980 Phase 3 Desloratadine 5 mg
16 A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria. Completed NCT01916967 Phase 3 Desloratadine;Placebo
17 A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Completed NCT03054428 Phase 3 Dupilumab;Placebo
18 A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00504075 Phase 3
19 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
20 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
21 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks;Standard of Care
22 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease Completed NCT00035308 Phase 3 Abetimus sodium (LJP 394)
23 Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients Completed NCT01307332 Phase 3 MabCampath-1h
24 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
25 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma Completed NCT00773747 Phase 3 vorinostat;bortezomib;placebo to vorinostat
26 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
27 Effect of Early Oral Colostrum Administration Versus Placebo on the Immune System in Premature Newborns Under 32 Weeks of Gestation: A Randomized Clinical Trial. Recruiting NCT03578341 Phase 3
28 A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma Recruiting NCT03629249 Phase 3 Placebo;QAW039 Dose 1;QAW039 Dose 2
29 A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS Recruiting NCT03627767 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Placebo
30 A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Recruiting NCT02549170 Phase 3
31 A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS Recruiting NCT03720470 Phase 3 PF-04965842 100 mg;PF-04965842 200 mg;Dupilumab;Oral Placebo;Injectable Placebo
32 A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus. Active, not recruiting NCT02794285 Phase 3 Placebo
33 A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults Active, not recruiting NCT02231281 Phase 3 cART(TDF/AZT+3TC+LPV/r)
34 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment Active, not recruiting NCT03170271 Phase 3 Benralizumab (Medi-563);Placebo
35 A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X) Terminated NCT01488708 Phase 3 LY2127399;Placebo
36 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
37 A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Terminated NCT01650805 Phase 3 ponatinib;imatinib (Gleevec/ Glivec)
38 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL Terminated NCT02366663 Phase 3 Carmustine;Etoposide;Cytarabine;Melphalan
39 Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus "Conventional Treatment" for Treating Steroid Resistant Acute Graft-versus Host Disease Terminated NCT02411084 Phase 3
40 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis Withdrawn NCT02677636 Phase 3 MSRD-100;Vehicle
41 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis Withdrawn NCT02677610 Phase 3 MSRD-100;Vehicle
42 Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial Unknown status NCT02594878 Phase 2 Pamidronatdinatrium
43 The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
44 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
45 Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy. Unknown status NCT01687192 Phase 2
46 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
47 Extract Allergen From Betula Verrucosa. Test Sensitivity and Specificity of Diagnostic in Prick Test Preparation Completed NCT02527187 Phase 2
48 High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT02294552 Phase 2 Cyclophosphamide;Busulfan;Fludarabine monophosphate;Tacrolimus;Mycophenolate mofetil
49 DMT210 Topical Gel in the Treatment of Mild to Moderate Atopic Dermatitis Completed NCT02949960 Phase 2 DMT210 Topical Gel;Vehicle Control
50 The Effects of Finesse on Glycemic Control in Adults With Diabetes Using MDI: Finesse vs. Pen or Syringe and Vial as Bolus Prandial Insulin Device Completed NCT01073566 Phase 2

Search NIH Clinical Center for Immune System Disease

Genetic Tests for Immune System Disease

Genetic tests related to Immune System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Immune System 29

Anatomical Context for Immune System Disease

MalaCards organs/tissues related to Immune System Disease:

41
T Cells, B Cells, Brain, Bone, Bone Marrow, Testes, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Immune System Disease:

19
Immune System

Publications for Immune System Disease

Articles related to Immune System Disease:

(show top 50) (show all 97)
# Title Authors PMID Year
1
On how the immune system preferentially interacts with antigen-specific molecules bound to antigen over unbound molecules, with emphasis on B cell receptor signalling. 17
31148206 2019
2
Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence. 17
31211608 2019
3
Metabolic adaptations of tissue-resident immune cells. 17
31213715 2019
4
Trehalose suppresses cadmium-activated Nrf2 signaling pathway to protect against spleen injury. 38
31195231 2019
5
The gastrointestinal fate of limonin and its effect on gut microbiota in mice. 38
31418448 2019
6
Analysis of Panax ginseng miRNAs and Their Target Prediction Based on High-Throughput Sequencing. 38
31434113 2019
7
High-Throughput Sequencing Reveals the Gut Microbiome of the Bactrian Camel in Different Ages. 38
31030270 2019
8
Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. 38
30515752 2019
9
Statistical analysis of disease-causing and neutral mutations in human membrane proteins. 38
30714211 2019
10
Medicinal plants of the Caatinga, northeastern Brazil: Ethnopharmacopeia (1980-1990) of the late professor Francisco José de Abreu Matos. 38
30885881 2019
11
A link between environmental pollution and civilization disorders: a mini review. 38
31141493 2019
12
Gut microbiota characterization and lipid metabolism disorder found in PCB77-treated female mice. 38
30935970 2019
13
Hsp70 interactions with membrane lipids regulate cellular functions in health and disease. 38
30710597 2019
14
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. 38
30885723 2019
15
Epigenetic Modification Related to Acetylation of Histone and Methylation of DNA as a Key Player in Immunological Disorders. 38
31002589 2019
16
The Variation of Nasal Microbiota Caused by Low Levels of Gaseous Ammonia Exposure in Growing Pigs. 38
31156592 2019
17
Computational comparison of two new fusion proteins for multiple sclerosis. 38
30271441 2018
18
Stiff person syndrome with elevated titers of antibodies against cardiolipin and β2 glycoprotein 1: a case report and literature review. 38
30179217 2018
19
Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-κB. 38
29777873 2018
20
Porcine cluster of differentiation (CD) markers 2018 update. 38
29518710 2018
21
Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. 38
29682215 2018
22
[Diffusion of Microorganism and Main Pathogenic Bacteria During Municipal Treated Wastewater Discharged into Sea]. 38
29965485 2018
23
Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. 38
29360814 2018
24
Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice. 38
30337870 2018
25
Research Techniques Made Simple: Murine Models of Human Psoriasis. 38
29273150 2018
26
Comparative transcriptome analysis of Eriocheir japonica sinensis response to environmental salinity. 38
30192896 2018
27
The vitamin D receptor and the etiology of RANTES/CCL-expressive fatty-degenerative osteolysis of the jawbone: an interface between osteoimmunology and bone metabolism. 38
29731660 2018
28
The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses. 38
29141575 2018
29
Integrated strategy of differentially expressed genes associated with ulcerative colitis. 38
28944823 2017
30
[Clinical applications of stem cells from human exfoliated deciduous teeth in stem cell therapy]. 38
29188652 2017
31
Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: a systematic review. 38
28674760 2017
32
Identification of Sequence Variants within Experimentally Validated Protein Interaction Sites Provides New Insights into Molecular Mechanisms of Disease Development. 38
28452122 2017
33
Fractalkine (C-X3-C motif chemokine ligand 1) as a potential biomarker for depression and anxiety in colorectal cancer patients. 38
28804633 2017
34
Kinetic analysis of IgM monoclonal antibodies for determination of dengue sample concentration using SPR technique. 38
27533620 2017
35
Investigation of Sex Differences In sIgA Response to the Trier Social Stress Test. 38
27075235 2017
36
The Importance of Immune System Diseases in the Etiology of Attention-Deficit/Hyperactivity Disorder. 38
28137376 2017
37
Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases. 38
26809250 2017
38
Toxicogenomic analysis of the pulmonary toxic effects of hexanal in F344 rat. 38
26880647 2017
39
Immunostimulatory Effect of Enzyme-Modified Hizikia fusiformein a Mouse Model In Vitro and Ex Vivo. 38
28138935 2017
40
Analysis of Clinical Characteristics of Immune-Related Dry Eye. 38
28638660 2017
41
Pharmacokinetics, Tissue Distribution, and Metabolism Study of Icariin in Rat. 38
29259982 2017
42
Prediction of microRNAs involved in immune system diseases through network based features. 38
27871823 2017
43
ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome. 38
28124611 2017
44
Six New Triterpene Derivatives from Aralia chinensis Var. dasyphylloides. 38
27941689 2016
45
Mining gut microbiome oligopeptides by functional metaproteome display. 38
27703179 2016
46
Evaluating frequency and quality of pathogen-specific T cells. 38
27786275 2016
47
Next Generation Sequencing Data Analysis in Primary Immunodeficiency Disorders - Future Directions. 38
26993986 2016
48
GSK3β Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells. 38
26805448 2016
49
The promises of quantitative systems pharmacology modelling for drug development. 38
27761201 2016
50
Transcriptomic analysis of the host response to an iridovirus infection in Chinese giant salamander, Andrias davidianus. 38
26589400 2015

Variations for Immune System Disease

Expression for Immune System Disease

Search GEO for disease gene expression data for Immune System Disease.

Pathways for Immune System Disease

Pathways related to Immune System Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF SERPINA3 IL6 IL4 IL2 IL17A
2
Show member pathways
13.71 TNF IL6 IL4 IL2 IL17A IL10
3
Show member pathways
13.56 TNF IL6 IL4 IL2 IL17A IL10
4
Show member pathways
13.45 TNF IL6 IL4 IL2 IL17A IL10
5
Show member pathways
13.4 TNF IL6 IL4 IL2 IL17A IL10
6
Show member pathways
13.34 TNF IL6 IL4 IL2 IL17A IL10
7
Show member pathways
12.78 TNF IL6 IL4 IL2 IL17A IL10
8
Show member pathways
12.66 TNF IL4 IL2 IL10 ICOSLG CD40LG
9
Show member pathways
12.64 TNF IL6 IL2 IL17A IL10 CD4
10
Show member pathways
12.63 TNF IL6 IL4 IL2 IL17A IL10
11 12.57 TNF IL4 IL2 IL17A IL10 FOXP3
12
Show member pathways
12.45 IL6 IL4 IL2 IL10 IFNB1
13
Show member pathways
12.44 IL2 ICOSLG CTLA4 CD40LG CD4
14
Show member pathways
12.4 TNF IL6 IL4 IL2 IL17A IL10
15
Show member pathways
12.38 TNF SERPINA3 IL6 IL4 IL2
16
Show member pathways
12.35 TNF IL6 IL4 IL17A
17
Show member pathways
12.29 TNF IL6 IL4 IL2 IL17A IL10
18
Show member pathways
12.28 TNF IL4 IL10 CD40LG
19 12.26 TNF IL6 IL10 IFNB1
20
Show member pathways
12.24 TNF IL6 IL2 IL10
21
Show member pathways
12.21 TNF IL6 IL4 IFNB1
22 12.17 ICOSLG CTLA4 CD8A CD40LG CD4
23
Show member pathways
12.13 IL6 IL4 IL2 IL17A IL10 CD4
24
Show member pathways
12.12 TNF IL6 IL2 IL17A IL10 CD4
25 12.06 TNF MBP IL6 IL4 IL2
26 12.04 TNF IL6 IL4 IL2 IL10 CD8A
27 12.03 TNF IL6 IL4 IL17A IL10
28
Show member pathways
12.02 IL4 IL2 CD8A CD4
29 11.93 TNF IL6 IL4 CD8A CD4
30 11.92 IL6 IL2 IL10 IFNB1
31 11.92 TNF IL6 IL17A CTLA4
32 11.91 TNF IL6 IL10
33
Show member pathways
11.87 IL6 IL17A FOXP3
34 11.82 IL6 IL4 IL2
35
Show member pathways
11.81 TNF IL4 IL2 FOXP3 CTLA4 CD40LG
36 11.78 TNF IL6 IL10
37 11.78 TNF IL6 IL2 IL10 IFNB1 CD8A
38 11.75 CTLA4 CD8A CD4
39
Show member pathways
11.73 TNF IL6 IL2 CD40LG
40
Show member pathways
11.72 IL4 IL2 FOXP3
41 11.72 TNF TGM2 IL6 IL4 IL2 IL17A
42 11.69 TNF IL6 IL4
43 11.69 IL4 IL10 CD40LG
44
Show member pathways
11.67 TNF IL2 CD8A
45 11.65 ICOSLG CTLA4 CD40LG
46 11.6 IL10 CD40LG CD4
47 11.6 TNF IL6 IL10 CD40LG
48 11.59 TNF IL6 IL4 IL10
49 11.58 TNF IL6 IL2
50 11.57 IL4 IL2 IL10 FOXP3 CD4

GO Terms for Immune System Disease

Cellular components related to Immune System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TNF SERPINA3 IL6 IL4 IL2 IL17A
2 cell surface GO:0009986 9.73 TNF MBP CD40LG CD4 CCR6 APOH
3 extracellular space GO:0005615 9.65 TNF SERPINA3 IL6 IL4 IL2 IL17A
4 external side of plasma membrane GO:0009897 9.28 TNF MOG IL17A ICOSLG CTLA4 CD8A

Biological processes related to Immune System Disease according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.92 IL2 IFNB1 ICOSLG CTLA4 CD4
2 inflammatory response GO:0006954 9.91 TNF SERPINA3 IL6 IL17A IL10 CD40LG
3 T cell receptor signaling pathway GO:0050852 9.85 MOG ICOSLG FOXP3 CD4
4 regulation of immune response GO:0050776 9.85 MOG IL4 ICOSLG CD8A CD40LG
5 positive regulation of inflammatory response GO:0050729 9.84 TNF TGM2 IL2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 IL6 IL4 IL2
7 response to glucocorticoid GO:0051384 9.82 TNF IL6 IL10
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 TNF TGM2 IL6
9 T cell costimulation GO:0031295 9.77 ICOSLG CTLA4 CD40LG
10 negative regulation of T cell proliferation GO:0042130 9.73 IL10 FOXP3 CTLA4
11 B cell differentiation GO:0030183 9.71 IL4 IL10 IFNB1 CD40LG
12 B cell proliferation GO:0042100 9.69 IL10 IFNB1 CD40LG
13 negative regulation of immune response GO:0050777 9.68 FOXP3 CTLA4
14 positive regulation of regulatory T cell differentiation GO:0045591 9.67 IL2 FOXP3
15 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL2
16 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 MBP IL10
17 negative regulation of interleukin-6 production GO:0032715 9.67 TNF IL10 FOXP3
18 T cell mediated immunity GO:0002456 9.66 FOXP3 CD8A
19 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 IL4 IL2
20 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
21 positive regulation of T cell proliferation GO:0042102 9.65 IL6 IL4 IL2 CD40LG CD4
22 negative regulation of T-helper 17 cell differentiation GO:2000320 9.64 IL2 FOXP3
23 endothelial cell apoptotic process GO:0072577 9.63 TNF IL10
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL4 IL10
25 positive regulation of neuroinflammatory response GO:0150078 9.62 TNF IL6
26 humoral immune response GO:0006959 9.62 TNF IL6 IFNB1 CCR6
27 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2 FOXP3
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 TNF IL10
29 regulation of immunoglobulin secretion GO:0051023 9.59 TNF CD40LG
30 type 2 immune response GO:0042092 9.58 IL4 IL10
31 regulation of isotype switching GO:0045191 9.57 IL4 IL10
32 cytokine-mediated signaling pathway GO:0019221 9.56 TNF IL6 IL4 IL2 IL17A IL10
33 T cell activation GO:0042110 9.55 IL4 ICOSLG FOXP3 CD8A CD4
34 receptor biosynthetic process GO:0032800 9.54 TNF IL10
35 regulation of regulatory T cell differentiation GO:0045589 9.54 IL2 FOXP3 CTLA4
36 immune response GO:0006955 9.4 TNF MBP IL6 IL4 IL2 IL17A
37 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 TNF IL6 IL4 IL2 IL17A IL10
38 positive regulation of transcription, DNA-templated GO:0045893 10.06 TNF IL6 IL4 IL10 FOXP3 CD4

Molecular functions related to Immune System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL6 IL4 IL2 IL10
2 cytokine activity GO:0005125 9.23 TNF IL6 IL4 IL2 IL17A IL10
3 protein binding GO:0005515 10.09 TNF TGM2 SERPINA3 MBP IL6 IL4

Sources for Immune System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....